...
首页> 外文期刊>European review for medical and pharmacological sciences. >Mirtogenol? supplementation in association with dorzolamide-timolol or latanoprost improves the retinal microcirculation in asymptomatic patients with increased ocular pressure
【24h】

Mirtogenol? supplementation in association with dorzolamide-timolol or latanoprost improves the retinal microcirculation in asymptomatic patients with increased ocular pressure

机译:Mirtogenol?与多佐胺-替莫洛尔或拉坦前列素联合使用可改善无症状眼压升高患者的视网膜微循环

获取原文
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: Supplementation with Mirtogenol? improves the retinal microcirculation and reduces intraocular pressure (IOP) in ocular hypertension, when administrated either alone or in association with an ophthalmic solution (latanoprost). In this study, microcirculatory parameters (perfusion of the circle of Zinn-Haller and retinal circulation) and oxidative stress were tested to assess the effects of Mirtogenol? plus traditional antihypertensive drugs in patients with elevated IOP. PATIENTS AND METHODS: 88 otherwise healthy patients with increased IOP were followed-up in a supplement registry for 12 weeks. Three groups received; (a) dorzolamide-timolol plus Mirtogenol?; (b) latanoprost drops plus Mirtogenol? or (c) latanoprost only. Oral supplementation consisted of two tablets/day of Mirtogenol? (80 mg of bilberry extract, Mirtoselect? plus 40 mg of Pycnogenol?). IOP, retinal blood flow, perfusion of the circle of Zinn-Haller, and oxidative stress were measured during the registry period. RESULTS: The three study groups were comparable; IOP and ocular blood flow velocity at inclusion were also comparable. Over the study period the decrease in IOP and the improvements in retinal microcirculation were statistically significant for all management groups, with a marginally more evident benefit in Mirtogenol?+latanosprost-treated patients. At 12 weeks, the altered perfusion at the circle of Zinn-Haller was improved in all groups; patients using Mirtogenol? showed a better perfusional pattern compared with subjects using only latanoprost. A reduction in oxidative stress was observed in supplemented subjects at the end of the study period; no significant change was seen in non-supplemented patients. All managements were well-tolerated without side effects. CONCLUSIONS: Supplementation with Mirtogenol?, in addition to local ophthalmic treatments, is safe and may contribute as a supplementary management to reach a normal IOP and ocular microcirculatory parameters.
机译:目的:补充吗?当单独或与眼药水(拉坦前列素)联合使用时,可改善高眼压患者的视网膜微循环并降低眼内压(IOP)。在这项研究中,测试了微循环参数(Zinn-Haller圆的灌注和视网膜循环)和氧化应激,以评估美能龙的作用。加上传统的降压药物治疗眼压升高的患者。患者与方法:88例其他原发性眼压增加的健康患者在补充注册表中随访了12周。三组; (a)多佐胺-噻吗洛尔加美托诺尔? (b)拉坦前列素滴眼液加Mirtogenol?或(c)仅拉坦前列素。口服补充剂包括每日服用两片美托诺尔? (80毫克的越桔提取物,Mirtoselect?加上40毫克的碧萝ogen?)。在登记期间测量眼压,视网膜血流量,Zinn-Haller环的灌注和氧化应激。结果:三个研究组具有可比性。眼压和眼内血流速度也相当。在整个研究期间,IOP的降低和视网膜微循环的改善在所有管理组中均具有统计学显着性,在接受Mirtogenol?+ latanosprost治疗的患者中,获益略微明显。在第12周时,所有组的Zinn-Haller圈的灌注改变均得到改善;患者使用美托诺尔?与仅使用拉坦前列素的受试者相比,显示出更好的灌注模式。在研究期结束时,补充对象中的氧化应激降低。未补充的患者未见明显变化。所有管理均耐受良好,无副作用。结论:除局部眼科治疗外,补充Mirtogenol?是安全的,并可作为补充治疗以达到正常IOP和眼部微循环参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号